Recent results from the PATHFINDER 2 study showed that the addition of GRAIL’s multi-cancer detection test to standard screening led to a seven-fold increase in cancers detected within a year, the company said.
As the debate around Galleri, the multi-cancer detection test developed by GRAIL Inc., rages on, fueled most recently by the full-steam-ahead support it has received from regulatory and legislative bodies, NCI Director Anthony Letai has turned his attention to the available data.
